Publications
5677 Results
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr TPS4185), poster 157B; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/EA2186
EA-2186: A randomized phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5- Fluorouracil, Leucovorin, and Liposomal Irinotecan in older patients with treatment naïve metastatic pancreatic cancer (GIANT): Trials in Progress
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr TPS6098), poster 89A; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Early Therapeutics and Rare Cancers
A Phase II/III Trial of Chemotherapy + Cetuximab vs. Chemotherapy + Bevacizumab vs. Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers: ECOG-ACRIN EA3202
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr TPS4617), poster #98B; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Genitourinary
A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr TPS4617), poster 98B; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Genitourinary
- Study Number(s)
- CTSU/EA8185
EA8185: Phase 2 Study of Bladder-SparIng ChemoradiatioN (chemoRT) with Durvalumab in Clinical Stage III, Node PosItive URothElial Carcinoma (INSPIRE), an ECOG-ACRIN/NRG Collaboration
- Journal / Conference
- Journal of the National Cancer Institute Aug 8;114(8):1059-1064
- Year
- 2022
- Research Committee(s)
- Cancer Care Delivery
- PMID
- PMID35552713
- PMC
- PMC9360467
Improving Patient Advocacy in NCI Scientific Steering Committees and Task Forces
- Journal / Conference
- Journal of Clinical Oncology Jul 20;40(21):2295-2306
- Year
- 2022
- Research Committee(s)
- Lung
- PMID
- PMID35658002
- PMC
- PMC9287284
- Study Number(s)
- S1800A
Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small Cell Lung Cancer Previously Treated with Immunotherapy—Lung-MAP S1800A
- Journal / Conference
- JCO Vol 40 Issue 6 Supp; ASCO Genitourinary (GU) Cancers Symposium 2022 (Feb 17-19, 2022, San Francisco, CA), poster
- Year
- 2022
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S2011
Randomized Phase II Trial Of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma (MIUC): SWOG Gap Trial (S2011)
- Journal / Conference
- Journal of Clinical Oncology Oct 1;40(28):3301-3309
- Year
- 2022
- Research Committee(s)
- Genitourinary
- PMID
- PMID35446628
- PMC
- PMC9553390
- Study Number(s)
- S1216
Orteronel for metastatic hormone sensitive prostate cancer: A multicenter, randomized, open-label phase III trial (SWOG-1216)
- Journal / Conference
- Society for Clinical Trials (MAY 15-18, 2022 San Diego, CA), poster
- Year
- 2022
- Research Committee(s)
- Multiple sites
A More Efficient Approach to Clinical Trial Data Collection: The SWOG-nCartes Pilot Collaboration
- Journal / Conference
- Society for Clinical Trials (MAY 15-18, 2022 San Diego, CA), poster
- Year
- 2022
- Research Committee(s)
- Cancer Care Delivery, Prevention, Screening, and and Surveillance
- Study Number(s)
- S1415CD, S1904, S2108CD